medigraphic.com
Revista Mexicana de Coloproctología Enfermedades del Ano, Recto y Colon

2026, Number 1

Next >>

Rev Mex Coloproctol 2026; 22 (1)

Rectal cancer: tailored treatment for each patient. Multidisciplinary team, a cornerstone

Lombana LJ

Language: Spanish
References: 12
Page: 3-5
PDF size: 486.34 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacfarlaneJK. Rectal cancer: the Basingstoke experience of totalmesorectal excision, 1978‑1997. Arch Surg. 1998; 133 (8):894-899.

  2. Sauer R, Becker H, Hohenberger W, Rodel C, WittekindC, Fietkau R et al. Preoperative versus postoperativechemoradiotherapy for locally advanced rectal cancer. NEngl J Med. 2004; 351 (17): 1731‑1740.

  3. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift Iet al. Preoperative high‑resolution magnetic resonanceimaging can identify good prognosis stage I, II, and III rectalcancer best managed by surgery alone: a prospective,multicenter, European study. Ann Surg . 2011; 253(4):711‑719. doi: 10.1097/SLA.0b013e31820b8d52.

  4. Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L,Swift IR et al. Preoperative magnetic resonance imagingassessment of circumferential resection margin predictsdisease‑free survival and local recurrence: 5‑year follow‑upresults of the MERCURY study. J Clin Oncol. 2014; 32 (1):34‑43.

  5. Ruppert R, Junginger T, Ptok H, Strassburg J, Maurer CA,Brosi P et al. Oncological outcome after MRI-basedselection for neoadjuvant chemoradiotherapy in the OCUMRectal Cancer Trial. Br J Surg. 2018; 105 (11): 1519-1529.

  6. Kennedy ED, Simunovic M, Jhaveri K, Kirsch R, Brierley J,Drolet S et al. Safety and feasibility of using magneticresonance imaging criteria to identify patients with “goodprognosis” rectal cancer eligible for primary surgery: the Phase2 nonrandomized QuickSilver clinical trial. JAMA Oncol.2019; 5 (7): 961‑966. doi: 10.1001/jamaoncol.2019.0186.

  7. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM,Putter H, Kranenbarg EM et al. Short‑course radiotherapyfollowed by chemotherapy before total mesorectal excisionversus preoperative chemoradiotherapy and TME inlocally advanced rectal cancer (RAPIDO): a randomised,open‑label, phase 3 trial. Lancet Oncol. 2021; 22 (1):29‑42. doi: 10.1016/S1470‑2045(20)30555‑6.

  8. Conroy T, Bosset JF, Etienne PL, Rio E, François É,Mesgouez‑Nebout N, et al.; UNICANCER‑PRODIGE23 Trial Investigators. Neoadjuvant chemotherapy withFOLFIRINOX and preoperative chemoradiotherapy forpatients with locally advanced rectal cancer (PRODIGE 23):a multicentre, randomised, open‑label, phase 3 trial. LancetOncol. 2021; 22 (5): 702‑715.

  9. García-Aguilar J, Patil S, Marc MJ, Kim JK, Thompson HM,Verheij FS et al. Organ preservation is achievable in patientswith rectal adenocarcinoma treated with total neoadjuvanttherapy (OPRA). J Clin Oncol. 2022; 40 (23): 2546‑2556.

  10. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, MusherBL et al. Preoperative treatment of locally advanced rectalcancer. N Engl J Med. 2023; 389 (4): 322-334.

  11. Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, ChoMT et al. Management of locally advanced rectal cancer:ASCO guideline. J Clin Oncol. 2024; 42 (28): 3355‑3375.doi: 10.1200/JCO.24.01160.

  12. Glynne‑Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C,Cervantes A, et al. Rectal cancer: ESMO clinical practiceguidelines for diagnosis, treatment and follow‑up. AnnOncol. 2017; 28 (suppl 4): iv22‑iv40. doi: 10.1093/annonc/mdx224.




2020     |     www.medigraphic.com